QurAlis

Executive Summary

QurAlis is a private biotechnology company headquartered in Cambridge, Massachusetts, focused on developing precision medicines for neurodegenerative diseases, primarily amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Founded in 2018, the company leverages a deep understanding of disease biology to target specific genetic mutations and biomarkers, aiming to treat well-defined patient populations. Its lead programs are small molecules designed to address underlying disease drivers, such as aberrant RNA processing and mitochondrial dysfunction. QurAlis is currently in Phase 1 clinical development, having advanced its lead candidate, QRL-101, into early-stage trials for ALS. The company's pipeline also includes preclinical candidates for FTD and other neurological indications. With a strong scientific foundation and a focus on precision medicine, QurAlis aims to address significant unmet needs in devastating neurodegenerative conditions where few disease-modifying therapies exist. As a private company, it has attracted venture capital backing and continues to progress its programs toward key clinical milestones.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for QRL-101 in ALS60% success
• Q3 2026IND filing for FTD program70% success
• Q2 2026Series C financing round80% success